Compare HRMY & ESRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRMY | ESRT |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 834.5M |
| IPO Year | 2020 | 2012 |
| Metric | HRMY | ESRT |
|---|---|---|
| Price | $39.92 | $4.06 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 3 |
| Target Price | ★ $44.11 | $6.35 |
| AVG Volume (30 Days) | 861.2K | ★ 3.9M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 2.49% |
| EPS Growth | ★ 7.97 | N/A |
| EPS | ★ 1.84 | N/A |
| Revenue | ★ $868,453,000.00 | $768,270,000.00 |
| Revenue This Year | $19.75 | $4.26 |
| Revenue Next Year | $12.88 | $1.52 |
| P/E Ratio | $21.74 | ★ N/A |
| Revenue Growth | ★ 21.51 | 0.05 |
| 52 Week Low | $25.52 | $3.93 |
| 52 Week High | $43.49 | $8.04 |
| Indicator | HRMY | ESRT |
|---|---|---|
| Relative Strength Index (RSI) | 45.44 | 36.02 |
| Support Level | $37.30 | $3.93 |
| Resistance Level | $43.38 | $5.85 |
| Average True Range (ATR) | 1.21 | 0.13 |
| MACD | -0.38 | 0.02 |
| Stochastic Oscillator | 12.45 | 33.33 |
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Empire State Realty Trust Inc is a real estate investment trust (REIT) that owns and operates office, retail, and multifamily properties located in New York City, prominently in Manhattan. Its portfolio includes office and retail space as well as residential units. The company's objective is to maximize cash flow and total returns to its shareholders and to increase the value of the properties. Its reportable segments consist of a real estate segment and an Observatory segment. The majority of revenue is derived from the Real Estate segment, which includes all activities related to the ownership, management, operation, acquisition, redevelopment, repositioning and disposition of its traditional real estate assets.